BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 36765893)

  • 1. Transcriptomic Deconvolution of Neuroendocrine Neoplasms Predicts Clinically Relevant Characteristics.
    Otto R; Detjen KM; Riemer P; Fattohi M; Grötzinger C; Rindi G; Wiedenmann B; Sers C; Leser U
    Cancers (Basel); 2023 Feb; 15(3):. PubMed ID: 36765893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serotonin immunoreactive pancreatic neuroendocrine neoplasm associated with main pancreatic duct dilation: a recognizable entity with excellent long-term outcome.
    Dioguardi Burgio M; Cros J; Panvini N; Depoilly T; Couvelard A; Ruszniewski P; de Mestier L; Hentic O; Sauvanet A; Dokmak S; Faccinetto A; Ronot M; Vilgrain V
    Eur Radiol; 2021 Nov; 31(11):8671-8681. PubMed ID: 33977308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medical Treatment of Advanced Pancreatic Neuroendocrine Neoplasms.
    Palmieri LJ; Dermine S; Barré A; Dhooge M; Brezault C; Cottereau AS; Coriat R
    J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32549203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Do Canine Pancreatic Neuroendocrine Neoplasms Resemble Human Pancreatic Neuroendocrine Tumours? A Comparative Morphological and Immunohistochemical Investigation.
    de Vries C; Konukiewitz B; Weichert W; Klöppel G; Aupperle-Lellbach H; Steiger K
    J Comp Pathol; 2020 Nov; 181():73-85. PubMed ID: 33288156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of contrast-enhanced harmonic endoscopic ultrasonography for predicting the prognosis of pancreatic neuroendocrine neoplasms.
    Ishikawa R; Kamata K; Hara A; Tanaka H; Okamoto A; Yamazaki T; Nakai A; Omoto S; Minaga K; Yamao K; Takenaka M; Minami Y; Watanabe T; Chiba Y; Chikugo T; Matsumoto I; Takeyama Y; Matsukubo Y; Hyodo T; Kudo M
    Dig Endosc; 2021 Jul; 33(5):829-839. PubMed ID: 33020955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarkers for Pancreatic Neuroendocrine Neoplasms (PanNENs) Management-An Updated Review.
    Bocchini M; Nicolini F; Severi S; Bongiovanni A; Ibrahim T; Simonetti G; Grassi I; Mazza M
    Front Oncol; 2020; 10():831. PubMed ID: 32537434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rb Loss and
    Hijioka S; Hosoda W; Matsuo K; Ueno M; Furukawa M; Yoshitomi H; Kobayashi N; Ikeda M; Ito T; Nakamori S; Ishii H; Kodama Y; Morizane C; Okusaka T; Yanagimoto H; Notohara K; Taguchi H; Kitano M; Yane K; Maguchi H; Tsuchiya Y; Komoto I; Tanaka H; Tsuji A; Hashigo S; Kawaguchi Y; Mine T; Kanno A; Murohisa G; Miyabe K; Takagi T; Matayoshi N; Yoshida T; Hara K; Imamura M; Furuse J; Yatabe Y; Mizuno N
    Clin Cancer Res; 2017 Aug; 23(16):4625-4632. PubMed ID: 28455360
    [No Abstract]   [Full Text] [Related]  

  • 8. The molecular biology of pancreatic neuroendocrine neoplasms: Challenges and translational opportunities.
    Young K; Starling N; Sadanandam A
    Semin Cancer Biol; 2020 Apr; 61():132-138. PubMed ID: 31577961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA methylation reveals distinct cells of origin for pancreatic neuroendocrine carcinomas and pancreatic neuroendocrine tumors.
    Simon T; Riemer P; Jarosch A; Detjen K; Di Domenico A; Bormann F; Menne A; Khouja S; Monjé N; Childs LH; Lenze D; Leser U; Rossner F; Morkel M; Blüthgen N; Pavel M; Horst D; Capper D; Marinoni I; Perren A; Mamlouk S; Sers C
    Genome Med; 2022 Mar; 14(1):24. PubMed ID: 35227293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic relevance of proliferation-related miRNAs in pancreatic neuroendocrine neoplasms.
    Grolmusz VK; Kövesdi A; Borks K; Igaz P; Patócs A
    Eur J Endocrinol; 2018 Oct; 179(4):219-228. PubMed ID: 30299890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Characteristics and Management of Functional Pancreatic Neuroendocrine Neoplasms: A Single Institution 20-Year Experience with 286 Patients.
    Qu Y; Li H; Wang X; Chen Y; Guo Q; Pei Y; Du J; Dou J; Ba J; Lv Z; Mu Y
    Int J Endocrinol; 2020; 2020():1030518. PubMed ID: 33204258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival comparison between primary hepatic neuroendocrine neoplasms and primary pancreatic neuroendocrine neoplasms and the analysis on prognosis-related factors.
    Li MX; Li QY; Xiao M; Wan DL; Chen XH; Zhou L; Xie HY; Zheng SS
    Hepatobiliary Pancreat Dis Int; 2019 Dec; 18(6):538-545. PubMed ID: 30981633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FOXA2-initiated transcriptional activation of INHBA induced by methylmalonic acid promotes pancreatic neuroendocrine neoplasm progression.
    Hu C; Ye M; Bai J; Liu P; Lu F; Chen J; Xu Y; Yan L; Yu P; Xiao Z; Gu D; Xu L; Tian Y; Tang Q
    Cell Mol Life Sci; 2024 Jan; 81(1):50. PubMed ID: 38252148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular subtyping in pancreatic neuroendocrine neoplasms: New insights into clinical, pathological unmet needs and challenges.
    Yan J; Yu S; Jia C; Li M; Chen J
    Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188367. PubMed ID: 32339609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EZH2 Inhibition as New Epigenetic Treatment Option for Pancreatic Neuroendocrine Neoplasms (PanNENs).
    April-Monn SL; Andreasi V; Schiavo Lena M; Sadowski MC; Kim-Fuchs C; Buri MC; Ketkar A; Maire R; Di Domenico A; Schrader J; Muffatti F; Doglioni C; Partelli S; Falconi M; Perren A; Marinoni I
    Cancers (Basel); 2021 Oct; 13(19):. PubMed ID: 34638497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New staging classification for pancreatic neuroendocrine neoplasms combining TNM stage and WHO grade classification [].
    Wang M; Ding D; Qin T; Wang H; Liu Y; Liu J; Liu J; Zhang H; Zhao J; Wu CH; Javed A; Wolfgang C; Guo S; Chen Q; Zhao W; Shi W; Zhu F; Guo X; Li X; He R; Xu S; Edil B; Tien YW; Jin G; Zheng L; He J; Qin R;
    Cancer Lett; 2021 Oct; 518():207-213. PubMed ID: 34271105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies.
    Lee L; Ito T; Jensen RT
    Expert Rev Anticancer Ther; 2019 Dec; 19(12):1029-1050. PubMed ID: 31738624
    [No Abstract]   [Full Text] [Related]  

  • 18. Progesteron receptor expression in insulin producing cells of neuroendocrine neoplasms.
    Tachibana T; Kasajima A; Aoki T; Tabata T; McNamara K; Yazdani S; Satoko S; Fujishima F; Motoi F; Unno M; Sasano H
    J Steroid Biochem Mol Biol; 2020 Jul; 201():105694. PubMed ID: 32437964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroendocrine Neoplasms: Dichotomy, Origin and Classifications.
    Klöppel G
    Visc Med; 2017 Oct; 33(5):324-330. PubMed ID: 29177160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Clinicopathologic and Molecular Update of Pancreatic Neuroendocrine Neoplasms With a Focus on the New World Health Organization Classification.
    Fang JM; Shi J
    Arch Pathol Lab Med; 2019 Nov; 143(11):1317-1326. PubMed ID: 31509453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.